Meronem Drug Interactions

Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem with the effect of increasing the elimination half-life and plasma concentration of meropenem. As the potency and duration of action of Meropenem (MERONEM) IV dosed without probenecid are adequate the co-administration of probenecid with Meropenem (MERONEM) IV is not recommended. The potential effect of Meropenem (MERONEM) IV on the protein binding of other drugs or metabolism has not been studied. However, the protein binding is so low that no interactions with other compounds would be expected on the basis of this mechanism.
Decreases in blood levels of valproic acid have been reported when it is co-administered with carbapenem agents resulting in a 60-100% decrease in valproic acid levels in about two days. Due to the rapid onset and the extent of the decrease, co-administration of Meropenem (MERONEM) IV in patients stabilised on valproic acid is not considered to be manageable and therefore should be avoided (see Precautions).
Meropenem (MERONEM) IV has been administered concomitantly with many other medications without apparent adverse interaction. However, no specific drug interaction studies other than probenecid were conducted.